论文部分内容阅读
本报导对12名男性健康自愿受试者单剂随机交叉口服琥乙红霉素分散片和琥乙红霉素片1000mg后的药代动力学参数和相对生物利用度进行了比较。血药浓度采用生物效价法测定,按统计矩计算出药代动力学参数。结果表明:口服琥乙红霉素分散片和琥乙红霉素片后,其AUC分别为:4.92±1.00与5.08±1.08mg·h·L_(-1)(P>0.05),T_(max):1.33±0.32与1.54±0.26h(P>0.05),C_(max):1.34±0.33与1.24±0.32mg·L~(-1)(P>0.05)。其相对生物等效性为96.85％。
The present study compared the pharmacokinetic parameters and relative bioavailability of 12 male volunteers with a randomized crossover study of 1000 mg erythromycin ethylsuccinate tablets and erythromycin ethylsuccinate tablets. The plasma concentration was determined by the bioequivalence method and the pharmacokinetic parameters were calculated according to the statistical moment. The results showed that the AUC of oral erythromycin ethylsuccinate tablets and erythromycin ethylsuccinate tablets were 4.92 ± 1.00 and 5.08 ± 1.08mg · h · L -1, respectively (P> 0.05) ): 1.33 ± 0.32 and 1.54 ± 0.26h (P> 0.05), C max: 1.34 ± 0.33 and 1.24 ± 0.32mg · L -1 (P> 0.05). The relative bioequivalence was 96.85%.